General Announcement::Glenmark Pharmaceuticals receives ANDA approval for Clobetasol Propionate Foam

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
10-Sep-2019 11:46:34
Status
New
Announcement Sub Title
Glenmark Pharmaceuticals receives ANDA approval for Clobetasol Propionate Foam
Announcement Reference
SG190910OTHRQII4
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Ltd.
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
10/09/2019 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals receives ANDA approval for Clobetasol Propionate Foam,0.05% (Emulsion Formulation)

Attachments

PR_SGX_10092019.pdf
Total size =217K